These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 22738631)
41. Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Bolchi C; Pallavicini M; Bernini SK; Chiodini G; Corsini A; Ferri N; Fumagalli L; Straniero V; Valoti E Bioorg Med Chem Lett; 2011 Sep; 21(18):5408-12. PubMed ID: 21802946 [TBL] [Abstract][Full Text] [Related]
42. Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc. Huang CY; Stauffer TM; Strickland CL; Reader JC; Huang H; Li G; Cooper AB; Doll RJ; Ganguly AK; Baldwin JJ; Rokosz LL Bioorg Med Chem Lett; 2006 Feb; 16(3):507-11. PubMed ID: 16289818 [TBL] [Abstract][Full Text] [Related]
43. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach. Puntambekar D; Giridhar R; Yadav MR Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255 [TBL] [Abstract][Full Text] [Related]
44. New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia. Longeon A; Copp BR; Roué M; Dubois J; Valentin A; Petek S; Debitus C; Bourguet-Kondracki ML Bioorg Med Chem; 2010 Aug; 18(16):6006-11. PubMed ID: 20634081 [TBL] [Abstract][Full Text] [Related]
45. 10H-Phenothiazines: a new class of enzyme inhibitors for inflammatory diseases. Sadanandam YS; Shetty MM; Rao AB; Rambabu Y Eur J Med Chem; 2009 Jan; 44(1):197-202. PubMed ID: 18400337 [TBL] [Abstract][Full Text] [Related]
46. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. Puntambekar DS; Giridhar R; Yadav MR Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576 [TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629 [TBL] [Abstract][Full Text] [Related]
48. Induction of DNA fragmentation in human myelogenous leukaemic cell lines by phenothiazine-related compounds. Sakagami H; Takahashi H; Yoshida H; Yamamura M; Fukuchi K; Gomi K; Motohashi N; Takeda M Anticancer Res; 1995; 15(6B):2533-40. PubMed ID: 8669819 [TBL] [Abstract][Full Text] [Related]
49. Novel Thiazolo[5,4-b]phenothiazine Derivatives: Synthesis, Structural Characterization, and In Vitro Evaluation of Antiproliferative Activity against Human Leukaemia. Brem B; Gal E; Găină L; Silaghi-Dumitrescu L; Fischer-Fodor E; Tomuleasa CI; Grozav A; Zaharia V; Filip L; Cristea C Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28672876 [TBL] [Abstract][Full Text] [Related]
50. Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. Esteva MI; Kettler K; Maidana C; Fichera L; Ruiz AM; Bontempi EJ; Andersson B; Dahse HM; Haebel P; Ortmann R; Klebe G; Schlitzer M J Med Chem; 2005 Nov; 48(23):7186-91. PubMed ID: 16279776 [TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Carrico D; Ohkanda J; Kendrick H; Yokoyama K; Blaskovich MA; Bucher CJ; Buckner FS; Van Voorhis WC; Chakrabarti D; Croft SL; Gelb MH; Sebti SM; Hamilton AD Bioorg Med Chem; 2004 Dec; 12(24):6517-26. PubMed ID: 15556768 [TBL] [Abstract][Full Text] [Related]
55. New asymmetric synthesis of protein farnesyltransferase inhibitors via palladium-catalyzed cross-coupling reactions of 2-iodo-imidazoles. Kerhervé J; Botuha C; Dubois J Org Biomol Chem; 2009 May; 7(10):2214-22. PubMed ID: 19421463 [TBL] [Abstract][Full Text] [Related]
56. Synthesis and biological evaluation of quinuclidine derivatives incorporating phenothiazine moieties as squalene synthase inhibitors. Ishihara T; Kakuta H; Moritani H; Ugawa T; Yanagisawa I Chem Pharm Bull (Tokyo); 2004 Oct; 52(10):1204-9. PubMed ID: 15467236 [TBL] [Abstract][Full Text] [Related]
57. On the discovery of new potent human farnesyltransferase inhibitors: emerging pyroglutamic derivatives. Homerin G; Lipka E; Rigo B; Farce A; Dubois J; Ghinet A Org Biomol Chem; 2017 Oct; 15(38):8110-8118. PubMed ID: 28905970 [TBL] [Abstract][Full Text] [Related]
58. Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential farnesyltransferase inhibitors: an approach to new lead compounds. Gilleron P; Millet R; Houssin R; Wlodarczyk N; Farce A; Lemoine A; Goossens JF; Chavatte P; Pommery N; Hénichart JP Eur J Med Chem; 2006 Jun; 41(6):745-55. PubMed ID: 16647166 [TBL] [Abstract][Full Text] [Related]
59. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. Kim CK; Choi YK; Lee H; Ha KS; Won MH; Kwon YG; Kim YM Mol Pharmacol; 2010 Jul; 78(1):142-50. PubMed ID: 20406854 [TBL] [Abstract][Full Text] [Related]
60. Albumin inhibition of the antileukemic activity of hydroxylated phenothiazines. Slater LM; Sweet PM; Stupecky MM; Murray SL; Wetzel MW Anticancer Drug Des; 1987 Apr; 1(4):297-301. PubMed ID: 3450301 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]